Regentis Biomaterials Ltd. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Regentis Biomaterials Ltd. (RGNT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $7.15 million for the 12-month period ending 2025-12-31, per its 20-F/A filed 2026-02-27.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-02-27
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|
| 2025-12-31 | $7.15M 20-F/A · filed 2026-02-27 |
| 2024-12-31 | -$116.00K 20-F/A · filed 2026-02-27 |
| 2023-12-31 | -$895.00K 20-F/A · filed 2026-02-27 |